世界のアルツハイマー病治療薬・診断市場予測...市場調査レポートについてご紹介

【英文タイトル】ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2014-2024
Opportunities for Leading Companies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market Overview
1.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Alzheimer’s Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer’s Disease?
2.1.2 What Causes Alzheimer’s Disease?
2.1.2.1 Alzheimer’s Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer’s Disease
2.1.4 The Socio-Economic Impact of Alzheimer’s Disease
2.1.5 Diagnosis of Alzheimer’s Disease

3. Alzheimer’s Disease Therapeutics and Diagnostics Market 2014-2024
3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market, 2013
3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.2.2 Healthcare Costs for Alzheimer’s Disease Will Surpass All Other Medical Expenses
3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.3 Drivers and Restraints

4. The Alzheimer’s Disease Drugs Market, 2014-2024
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer’s disease
4.2 The Alzheimer’s Disease Drugs Market, 2013
4.3 Changing Market Shares of the Leading Alzheimer’s Disease Drugs, 2014-2024
4.4 The Alzheimer’s Disease Drugs Market Forecast 2014-2024
4.5 Namenda
4.5.1 Namenda Sales Forecast, 2014-2024
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2014-2024
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2014-2024
4.8 Alzheimer’s Disease Drugs Pipeline, 2014
4.8.1 Recent High-Profile Failures of Clinical Trials for Alzheimer’s Disease Drug Candidates
4.8.1.1 Solanezumab (Eli Lilly)
4.8.1.2 LY-2886721 (Eli Lilly)
4.8.1.3 GSK2647544 (GSK)
4.8.1.4 Bapineuzumab (Elan/J&J/Pfizer)
4.8.1.5 Gammagard (Baxter)
4.9 FDA to Relax Rules for the Approval of Alzheimer’s Drugs
4.10 Will Novel Drug Development Strategies Prove Successful?
4.11 Promising Therapies in the Alzheimer’s Disease Drugs Pipeline, 2013
4.11.1 Solanezumab (Eli Lilly)
4.11.1.1Solanezumab Sales Forecast 2014-2024
4.11.2 Gantenerumab (Roche)
4.11.2.1The Gantenerumab Pipeline Forecast, 2014-2024
4.11.3 MK-8931 (Merck)
4.11.3.1 The MK-8931 Pipeline Forecast, 2014-2024
4.11.4 TTP488 (TransTechPharma)
4.11.5 LMTX (TauRx)
4.11.6 EVP-6124 (Forum Pharmaceuticals)
4.12 Deep Brain Stimulation (Functional Neuromodulation)
4.13 Leading Companies in the Alzheimer’s Disease Drugs Market, 2013
4.13.1 Pfizer, Inc
4.13.1.1Sales and Recent Performance Analysis, 2013
4.13.1.2 Pfizer: Aricept
4.13.1.3 Pfizer: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2 Eisai
4.13.2.1 Sales and Recent Performance Analysis, 2013
4.13.2.2 Eisai: Aricept
4.13.2.3 Eisai: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2.4 Collaboration with Biogen
4.13.2.5 Partnership with GE Healthcare for Diagnostic Development
4.13.3 Forest Laboratories (Acquired by Actavis)
4.13.3.1Acquisition by Actavis
4.13.3.2 Forest: Namenda
4.13.3.3 Namenda’s Sales and Recent Performance Analysis, 2013
4.13.4 Lundbeck A/S
4.13.4.1 Sales and Recent Performance Analysis, 2013
4.13.4.2 Lundbeck: R&D Capabilities
4.13.4.3 Lundbeck’s Alzheimer’s Disease Drug Pipeline
4.13.4.4 Lundbeck: Ebixa
4.13.5 Daiichi Sankyo
4.13.5.1 Financial Sales and Recent Performance, 2013
4.13.5.2 Daiichi Sankyo: Memary
4.13.6 Novartis AG
4.13.6.1 Sales and Recent Performance Analysis, 2013
4.13.6.2 Novartis: Exelon
4.13.6.3 eHealth Programme Delivering Innovation
4.13.6.4 Novartis: Alzheimer’s Disease Drug Pipeline
4.13.7 TauRx
4.13.7.1 Partnership with Bayer Schering Pharma AG
4.13.8Transtech Pharma
4.13.8.1TTP Translational Technology
4.13.8.2 TranstechPharma: Alzheimer’s Disease Pipeline Portfolio

5. The Alzheimer’s Disease Diagnostics Market, 2014-2024
5.1 There is Still a Strong Market Need for Effective Diagnosis
5.2 The Alzheimer’s Disease Diagnostics Market, 2013
5.3 Changing Market Shares of Leading Alzheimer’s Diagnostic Markets, 2014-2024
5.4 The Alzheimer’s Diagnostics Market, 2014-2024
5.5 New Criteria and Guidelines to Diagnose Alzheimer’s Disease
5.6 Biomarkers for Alzheimer’s Disease
5.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
5.7 Alzheimer’s Disease: Advances in Diagnostic Imaging Technologies
5.7.1 Structural Imaging
5.7.2 Functional Imaging
5.7.3 Molecular Imaging Technologies
5.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
5.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
5.7.3.3 Flutemetamol (GE Healthcare)
5.7.3.4 Florbetaben (Piramal Imaging)
5.8 Other Alzheimer’s Diagnostics in Development
5.8.1 CSF Proteins
5.8.2 Blood Based Biomarkers for Alzheimer’s Disease
5.8.3 Genetic Risk Profiling
5.8.4 Eye Tests
5.9 Leading Companies in the Alzheimer’s Disease Diagnostics Market, 2014
5.9.1 Eli Lilly
5.9.1.1 Recent Performance and Sales Analysis, 2013
5.9.1.2 Alzheimer’s Disease Research Effort
5.9.1.3 Solanezumab
5.9.1.4 Amyvid (Florbetapir F18)
5.9.1.5 Amyvid Receives Marketing Authorization from the European Commission
5.9.1.6 LY-2886721: Terminated Drug
5.9.1.7 N3pG-AB mAb:Phase I
5.9.1.8 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
5.9.2 Amarantus BioScience Holdings, Inc.
5.9.2.1 Recent Performance and Sales Analysis, 2013
5.9.2.2 LymPro
5.9.2.3 Intellectual Property Acquisitions
5.9.3 Piramal Enterprises
5.9.3.1Piramal Imaging SA
5.9.3.2 U.S. and EMA Approval of Florbetaben
5.9.3.3 Manufacturing and Distribution Agreements
5.9.4 GE Healthcare
5.9.4.1 GE’s Commitment to Imaging Research in the Alzheimer’s Field
5.9.4.2 Regulatory Approval of Flutemetamol
5.9.4.3 Licensing Agreements for Flutemetamol
5.9.5 Navidea
5.9.5.1 NAV4694 (Fluorine-18)
5.9.5.2 Collaboration Agreements
5.9.5.3 NAV4694 Clinical Development
5.9.6 Diagenic
5.9.6.1 Organisational Restructuring

6. The Leading National Markets, 2014-2024
6.1 Regional Breakdown of the Global Alzheimer’s Disease Therapeutics and Diagnostic Market, 2013
6.1.1 The US and Europe Represent More than 70% of the Total Market
6.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Regional Forecast, 2014-2024
6.3 Changing Market Shares of Leading National Markets 2014-2024
6.4 The US Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.4.1 One in Eight Over the Age of 65 has AD in the US
6.4.2 The US Will Remain the Largest Market Over the Forecast Period
6.5 The European Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.5.1 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.5.2 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.3 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-
2024
6.5.4 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, #
2014-2024
6.5.5 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.6 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market
Forecast, 2014-2024
6.6 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.7 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.8 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.9 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.10 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.11 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024

7. Qualitative Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
7.1 SWOT Analysis
7.2 Strengths
7.2.1 Alzheimer’s Disease is a High Profile Disease
7.2.2 Expanding Patient Population
7.2.3 Strong R&D Pipeline in Both Sectors of the Market
7.3 Weaknesses
7.3.1 Current Drugs Only Treat the Symptoms of Alzheimer’s Disease
7.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
7.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
7.4. Opportunities
7.4.1 Regulations Seeking Improved Standards of Alzheimer’s Disease Drug Development
7.4.2 Neurodegenerative Diseases Have Strong R&D
7.4.3 Emerging Markets Will Help Drive the Market
7.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
7.5 Threats
7.5.1 Patent Expiries Will Lead to Further Generic Competition
7.5.2 New AD Therapies Face Political, Commercial and Social Pressures
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors
7.6.2 Threats of New Entrants
7.6.3 Powers of Suppliers
7.6.4 Bargaining Power of Buyers
7.6.5 Threat of Substitutes

8. Expert Opinions
8.1 Dr Simon Ridley, Head of Research, Alzheimer’s Research UK
8.1.1 Alzheimer’s Treatment in Late Stage Development
8.1.2 The Benefits of Alzheimer’s Diagnosis: A Future Prospect
8.1.3 Alzheimer’s and its Relationship with Other Diseases
8.1.4 Strategies to Incentivise Alzheimer’s Research and Investment
8.2 David Hanlon, Director of Business Development and Strategic Collaborations, Quanterix
8.2.1 Ultra Sensitive Automated Immunoassay Platform for Alzheimer’s
8.2.2 Alzheimer’s Disease Blood-based Biomarkers
8.2.3 Research Based Setting of the Simoa Technology
8.2.4 Quanterix: Alzheimer’s Partners and Collaborations
8.3 Elizabeth Edgerly, Ph.D., Chief Program Officer, The Alzheimer’s Association Northern California and Northern Nevada
8.3.1 Alzheimer’s Severe Under diagnosis
8.3.2 Novel Biomarkers: Critical for Alzheimer’s Diagnosis
8.3.3 Alzheimer’s Treatment Paradigm: Needs to be More Universally Effective
8.3.4 A Push to Improve the Success of Alzheimer’s Research
8.3.5 Alzheimer’s Treatment: The Greatest Challenge

9. Conclusions
9.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
9.2 Disease Modifying Drugs Will Transform the Declining Alzheimer’s Market
9.3 Demographics Will Help Drive the Market Over the Forecast Period
9.4 Medicines and Diagnostic Tests for Alzheimer’s Disease Hold Great Potential from 2014 to 2024


【レポート販売概要】

■ タイトル:世界のアルツハイマー病治療薬・診断市場予測
■ 英文:ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2014-2024
Opportunities for Leading Companies
■ 発行日:2014年8月
■ 調査会社:visiongain
■ 商品コード:VISG409044
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。